Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2025)

Spero Therapeutics' Accumulated Expenses history spans 10 years, with the latest figure at $5.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2.24% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 2.24%, while the annual FY2025 figure was $5.6 million, 2.24% up from the prior year.
  • Accumulated Expenses reached $5.6 million in Q4 2025 per SPRO's latest filing, down from $5.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.3 million in Q3 2024 to a low of $1.3 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $6.8 million, with a median of $5.7 million recorded in 2022.
  • The largest YoY upside for Accumulated Expenses was 622.68% in 2024 against a maximum downside of 85.31% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $14.4 million in 2021, then plummeted by 59.6% to $5.8 million in 2022, then increased by 13.11% to $6.6 million in 2023, then dropped by 16.79% to $5.5 million in 2024, then increased by 2.24% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Accumulated Expenses are $5.6 million (Q4 2025), $5.6 million (Q3 2025), and $4.2 million (Q2 2025).